VTYX Q3 2022 Earnings — Ventyx Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

VTYXVentyx Biosciences, Inc.

$1B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$31M

Net Income

-$30M

EPS (Diluted)

$-0.57

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$420M

Total Liabilities

$37M

Stockholders' Equity

$384M

Cash & Equivalents

$263M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$31M	-$13M	-145.7%
Net Income	-$30M	-$13M	-138.5%